PT Pyridam Farma Tbk Enters into a Marketing and Promotion Services Agreement with Mundhipharma Healthcare Indonesia
Referring to Financial Service Authority (“OJK”) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company and Annex to Regulation I-E of Decree of the Board of Directors of PT Bursa Efek No. Kep. 00015/BEI/01-2021 on Obligations of Information Submission, we, PT Pyridam Farma Tbk (“Company”) hereby inform that the Company intends to cooperate with PT Mundipharma Healthcare Indonesia (“Mundipharma”), an Indonesian company that holds the trademark of Betadine products (“Products”) in Indonesia (“Cooperation”).
In connection with the Cooperation, the Company and Mundipharma has signed a Marketing and Promotion Services Agreement on April 4th 2022 (“Agreement”), we hereby inform the following information:
a. Contracting Parties:
- PT Mundipharma Healthcare Indonesia; and
- PT Pyridam Farma Tbk.
b. Relationship of the Contracting Parties:
As per the date of this disclosure information, the Company and Mundipharma has no Affiliate relationship as stipulated under Law No. 8 of 1995 regarding Capital Market.
c. Contract type:
Agreement for marketing and promotion services for Products in Indonesia.
d. Contract value:
The Company is entitled to a compensation fee which will be calculated based on the sales value with the formula as stipulated in the Agreement.
e. The cause of obtaining the Contract:
The Company is appointed as Mundipharma’s exclusive partner to carry out any commercial activities to market, promote or communicate the sale, supply, or use of Mundipharma Products including advertising, discussing Mundipharma Products with hospitals, public health institutions and/or other health clinics.
There is no material impact of the incident, information or material facts on the operational, legal, financial condition, and business continuity of the Company.
The similar information is also submitted by Company through Indonesia Stock Exchange’s Website and reported to Financial Services Authority (OJK).
Jakarta, April 5th 2022
PT Pyridam Farma Tbk.
Corporate Secretary